论文部分内容阅读
目的研究新型有机硒化合物Eb的组织分布特点、体外抗肿瘤及免疫活性,同时对其体内的抗肿瘤前景进行探讨.方法昆明种小鼠连续灌胃给药Eb后,用荧光法测定心、肝、脾、肾、肺、胃、脑、肌、骨组织的硒含量,来考察Eb组织分布特异性.用MTT法检测其体外抗肿瘤活性.用淋巴细胞转化,溶血素抗体生成实验及吞噬细胞吞噬实验检测其免疫活性.结果连续灌胃Eb治疗剂量(0.1 g·kg-1·d-1)7天后,肝、脾、肺、肾、骨组织的硒含量增高,其中肝、脾组织的硒含量增高显著.心、胃、脑、肌肉组织的硒含量基本没变化;Eb对体外培养的人肝癌Bel-7402细胞、胃癌BGC-823细胞、肺癌Calu-3细胞具有生长抑制作用;Eb具有促进淋巴细胞转化、溶血素抗体生成及增强吞噬细胞吞噬功能的作用.结论Eb具有体外抗肿瘤,免疫增强活性及在肝、脾、肺、肾、骨组织的靶向性蓄积作用,表明Eb有作为抗肝、肺、肾、骨等组织肿瘤及增强免疫功能药物进一步研究的意义.“,”Aim To study the distribution pattern, antineeplsstic activity and immunocompetence of a novel organoselenium compound Eb and investigate its in vivo antineoplastic potential. Methods Eb was administered to Kunming miceneys, lungs, stomach, brain, muscle, and bone were determined by fluorometric method on the eighth day. MTT assay was used to study tumor growth inhibition of Eb in vitro, and lymphocyte transformation, hemolysin formation and phagocytosis nium in liver, spleen, lungs, kidneys, and bone of mice increased, especially those in liver and spleen increased significantly, compared with controls; but no significant changes of such contents were found in muscle, heart, brain, and stomach.Eb demonstrated inhibitory effects on human Bel-7402, BGC-823, and Calu-3 cancer cell lines in vitro. Eb also showed ability to enhance lymphocyte transformation and serum hemolysin formation in vitro and increase the phagocytosis of macrophages. Conclusion The validated antitumor and immunostimulatory activities of Eb suggest a hypothesis that Eb may behave as a biological response modifier when used as an antitumor agent. Eb is worthy of further study in developing a new antineoplastic and immunity enhancing agent in the light of its antitumor activity, immunocompetence and specific distribution in liver, lungs, kidneys, bone, and spleen.